CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders
CytoSorbents Corporation (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 5, 2018. At the Annual Meeting, the following matters were submitted to a vote of stockholders:
| 1. | The election of five (5) directors to serve until the Company’s 2019 Annual Meeting of Stockholders, or until their respective successors shall have been duly elected and qualified; |
| 2. | The approval of the compensation of the Company’s named executive officers, on an advisory basis; and |
| 3. | The ratification of the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the year ending December 31, 2018. |
At the close of business on April 13, 2018, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 29,983,134 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. The holders of 24,047,845 shares of the Company’s common stock were represented in person or by proxy at the Annual Meeting, constituting a quorum.
At the Annual Meeting, the five directors were elected, and the other proposals submitted to stockholders were approved.
Proposal No. 1 — Election of Directors
The vote with respect to the election of directors was as follows:
| Nominees | For | Withheld | Broker Non-Votes |
| Phillip P. Chan | 8,297,589 | 89,420 | 15,660,836 |
| Al W. Kraus | 7,370,070 | 1,016,939 | 15,660,836 |
| Edward R. Jones | 8,235,529 | 151,480 | 15,660,836 |
| Michael G. Bator | 8,236,717 | 150,292 | 15,660,836 |
| Alan D. Sobel | 8,216,581 | 170,428 | 15,660,836 |
Proposal No. 2 — Approval of the Compensation of the Company’s Named Executive Officers
The vote with respect to the proposal to approve the compensation of the Company’s named executive officers, on an advisory basis, was as follows:
| For | Against | Abstain | Broker Non-Votes |
| 7,678,801 | 628,638 | 79,570 | 15,660,836 |
Proposal No. 3 — Ratification of the Appointment of Independent Registered Public Accounting Firm
The vote with respect to the ratification of the appointment of WithumSmith+Brown PC as the Company’s independent registered public accounting firm for the year ending December 31, 2018 was as follows:
| For | Against | Abstain |
| 23,719,711 | 247,383 | 80,751 |
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
